Relapse factors for ileal neuroendocrine tumours after curative surgery: A retrospective French multicentre study

AimTo evaluate the characteristics of postoperative relapse, predictive factors and time to relapse after curative surgery for well-differentiated neuroendocrine tumours of the ileum, without hepatic or other distant metastases.MethodsClinical data of patients entered into the Groupe d’étude des Tumeurs Endocrines database were collected and analysed retrospectively to identify factors predictive of relapse.ResultsAmong 100 patients followed for a median of 56.5 (range 1–290) months, 42 relapsed after a median follow-up of 57.5 (range 6–176) months, with liver lesions in 27 (64.3%). Median disease-free survival (Kaplan–Meier) was 88 months (95% confidence interval 72–115). Disease-free survival was shorter for emergency surgery patients (p < 0.01), patients with distant mesenteric lymph-node metastases (p < 0.01), with fortuitous diagnosis (p = 0.02), with tumour diameter >20 mm (p = 0.02), and those with multiple tumours (p = 0.07). Multivariate analysis retained emergency surgery (odds-ratio 4.04 [95% confidence interval 2.01–8.11]), distant mesenteric lymph-node metastases (odds-ratio 2.53 [95% confidence interval 1.22–5.25]), and multiple tumours (odds-ratio 2.14 [95% confidence interval 1.01–4.50]), as being significantly associated with relapse.ConclusionPatients who underwent emergency surgery, with distant mesenteric lymph-node metastases or with multiple ileal tumours relapsed earlier. Closer monitoring for the patients with these risk factors may be required.